Needham & Company Reiterates a 'Buy' on Æterna Zentaris (AEZS); Busy Summer Brings Completion of Perifosine and AEZS-108 Pivotal Trials
Go back to Needham & Company Reiterates a 'Buy' on Æterna Zentaris (AEZS); Busy Summer Brings Completion of Perifosine and AEZS-108 Pivotal Trials| AETERNA ZENTARIS (NASDAQ: AEZS) | Delayed: 5.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.72 | 52 Week High | $15.70 | |||
| Open | $5.72 | 52 Week Low | $0.04 | |||
| Day High | $5.72 | P/E | N/A | |||
| Day Low | $5.72 | EPS | $0.00 | |||
| Volume | 47 | |||||
